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Is nitric oxide the forgotten 
nephroprotective treatment during cardiac 
surgery?
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Acute kidney injury (AKI) is a frequent complication in 
patients undergoing cardiac surgery with cardiopulmo-
nary bypass (CPB), with a reported incidence of 30–50%, 
and an associated increase in mortality [1]. Proposed 
mechanisms of cardiac surgery-associated AKI include 
neurohormonal activation, inflammation, ischemia–
reperfusion injury, hypoperfusion, venous congestion, 
microembolization and hemolysis. Nitric oxide (NO) is 
an important homeostatic mediator of renal hemody-
namics [2]. NO deficiency occurs in various experimental 
models of renal injury, including during CPB. Data from 
animal studies suggest that abnormalities in endogenous 
NO production lead to kidney injury, due to an imbal-
ance of production between the inducible and endothe-
lial nitric oxide synthase [3].
The effect of NO therapy on AKI is controversial and 
may depend on the setting. In a randomized control 
trial including patients with multiple heart valve sur-
gery (n = 244), NO delivered from the initiation of CPB 
reduced post-operative AKI and transition to stage 3 
chronic kidney disease [4]. Contrary to these findings, 
a broadly inclusive meta-analysis (including studies of 
patients with sepsis and acute respiratory distress syn-
drome, ARDS, and surgical patients) showed no benefit 
of NO on post-operative renal function [5]. Of concern, 
the same study found that NO use was actually associ-
ated with worse renal function in patients with ARDS 
[6]. Given these conflicting results, how should the ben-
efit of NO for prevention of AKI in cardiac surgery be 
adjudicated?
The meta-analysis by Hu et  al. in this issue of Annals 
of Intensive Care addresses several of these discrepancies 
[7]. The authors analyzed five randomized controlled tri-
als that investigate the effects of perioperative NO ther-
apy on AKI after cardiac surgery. Notably, the included 
studies differ in two major parameters: the timing of NO 
administration and the definition of AKI. Of those ana-
lyzed, the two older studies initiated NO therapy imme-
diately before weaning from CPB, and defined AKI as 
urine output less than 0.3  mL/kg/h or need for renal 
replacement therapy. These latter criteria likely underdi-
agnose the incidence of clinically significant AKI. In the 
three more recent studies (2018–2019), NO was initiated 
at the beginning of CPB and use the KDIGO criteria to 
define AKI. The pooled effect showed that perioperative 
NO therapy significantly reduced the risk of AKI after 
CPB with RR of 0.76 (95% CI 0.62–0.93, p = 0.008). Inter-
estingly, NO therapy only showed benefit when initiated 
at the beginning of CPB (RR 0.71, 95% CI 0.54–0.94, 
p = 0.02). This result may imply that a key window exists 
where NO therapy can provide renal protection.
To interpret their findings, the authors emphasize the 
role of hemolysis in development of AKI after CPB (Fig. 1). 
Red blood cells are sheared as they go through the bypass 
circuit and release free hemoglobin (Hb) into the circula-
tion. Free Hb in turn scavenges NO produced by endothe-
lial cells, depleting plasma levels and ultimately resulting 
in vasoconstriction and reduced organ perfusion. Further-
more, free Hb and its degradation byproducts cause glo-
merular injury by forming reactive oxygen species, which 
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can directly damage renal tubular cells and endothelium 
[3]. Thus, supplying exogenous NO in the peri-bypass 
period may not only protect organ perfusion by restor-
ing the NO levels depleted by hemolysis, but also maybe 
by directly chelating free Hb and dampen its nephro-
toxic effects. This is in contrast to ARDS where there is 
no apparent hemolysis. Moreover, prolonged NO therapy 
lasting days or even weeks (more commonly used in ARDS 
as compared with cardiac surgery) [6] has been associ-
ated with tubular apoptosis [8] and production of reactive 
nitrogen species leading to inflammation and renal injury.
The conclusions drawn by Hu et  al. encounter several 
challenges [7]. First, the small number of studies included 
in the analysis yield low statistical power. To provide 
additional statistical context for their findings, the 
authors performed trial sequential analysis, a method for 
adjusting significance thresholds in meta-analyses when 
the optimal sample size has not been reached. Given that 
the TSA monitoring boundary was not exceeded, the 
authors duly maintain that further studies are needed to 
confirm their basic finding. Second, the effect of NO on 
right ventricular function and venous congestion, both 
strongly associated with renal dysfunction [9, 10], are 
not explored in this meta-analysis. Given that right heart 
dysfunction is common after CPB, and that NO reduces 
right heart workload, the renal protective effects of NO 
may be mediated through improved right heart function. 
Unfortunately, of the studies included, only two reported 
hemodynamic data pertinent to right ventricular func-
tion, and the authors were unable to include this critical 
endpoint in their analysis. Finally, as discussed above, the 
finding that NO therapy lacks benefit when initiated only 
at the end of CPB is strongly confounded by the various 
definition of AKI used and the mode of administration of 
NO (i.e. inhaled or through the CPB circuit). This analysis 
is nevertheless important because it suggests that better 
delineation of the timing of NO therapy and its efficacy 
for preventing AKI warrants further investigation.
Limitations aside, what can clinicians learn from this 
information to help care for patients undergoing cardiac 
surgery? While no published trial to date has reported 
any adverse effects of NO during CPB, given the costs 
associated with NO therapy, its routine implementation 
for the sole indication of protecting the kidney is not 
practical in the absence of further data. The findings by 
Hu et al. may be limited by the small, heterogeneous pool 
of available literature, but they inform important new 
hypotheses about the timing and mechanisms of peri-
bypass NO therapy. New studies inspired by this work 
are badly needed to better understand and manage AKI 
in this vulnerable patient population.
Fig. 1 Proposed mechanisms of renal protection using nitric oxide during cardiac surgery with cardio‑pulmonary bypass. Free Oxy-Hb 
oxyhemoglobin, Met-Hb methemoglobin
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